RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SCI Pharmtech - Stock

SCI Pharmtech Net Income 2024

SCI Pharmtech Net Income

294.72 M TWD

Ticker

4119.TW

ISIN

TW0004119003

In 2024, SCI Pharmtech's profit amounted to 294.72 M TWD, a -4.55% increase from the 308.78 M TWD profit recorded in the previous year.

The SCI Pharmtech Net Income history

YEARNET INCOME (undefined TWD)
2023294.72
2022308.78
202155.7
2020360.12
2019571.1
2018447.24
2017190.98
2016416.96
2015373.9
2014264.84
2013159.9
2012194.4
201190
2010171.2
2009166.3
2008156.6
2007150.5
200646
200539.8
200441.8

SCI Pharmtech Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SCI Pharmtech, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SCI Pharmtech from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SCI Pharmtech’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SCI Pharmtech. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SCI Pharmtech’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SCI Pharmtech’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SCI Pharmtech’s growth potential.

SCI Pharmtech Revenue, Profit, and EBIT History

DateSCI Pharmtech RevenueSCI Pharmtech EBITSCI Pharmtech Net Income
20231.2 B TWD160.3 M TWD294.72 M TWD
2022899.74 M TWD118.97 M TWD308.78 M TWD
2021864.22 M TWD73.66 M TWD55.7 M TWD
20202.69 B TWD1.05 B TWD360.12 M TWD
20192.36 B TWD697.12 M TWD571.1 M TWD
20181.94 B TWD515.57 M TWD447.24 M TWD
20171.3 B TWD234.54 M TWD190.98 M TWD
20161.9 B TWD516.46 M TWD416.96 M TWD
20151.81 B TWD439.69 M TWD373.9 M TWD
20141.49 B TWD295.37 M TWD264.84 M TWD
20131.29 B TWD205.9 M TWD159.9 M TWD
20121.26 B TWD251.8 M TWD194.4 M TWD
20111.04 B TWD186.1 M TWD90 M TWD
2010994.7 M TWD212.7 M TWD171.2 M TWD
2009905.7 M TWD214.5 M TWD166.3 M TWD
2008945.4 M TWD195.1 M TWD156.6 M TWD
2007802.9 M TWD169.3 M TWD150.5 M TWD
2006514.9 M TWD41.4 M TWD46 M TWD
2005454.1 M TWD46 M TWD39.8 M TWD
2004457.9 M TWD60.2 M TWD41.8 M TWD

SCI Pharmtech stock margins

The SCI Pharmtech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SCI Pharmtech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SCI Pharmtech.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SCI Pharmtech's sales revenue. A higher gross margin percentage indicates that the SCI Pharmtech retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SCI Pharmtech's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SCI Pharmtech's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SCI Pharmtech's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SCI Pharmtech. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SCI Pharmtech's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SCI Pharmtech Margin History

SCI Pharmtech Gross marginSCI Pharmtech Profit marginSCI Pharmtech EBIT marginSCI Pharmtech Profit margin
202329.09 %13.31 %24.48 %
202232.36 %13.22 %34.32 %
202124.08 %8.52 %6.44 %
202047.39 %39.1 %13.39 %
201939.72 %29.59 %24.24 %
201838.61 %26.58 %23.05 %
201730.41 %18.03 %14.68 %
201641.54 %27.14 %21.91 %
201536.18 %24.29 %20.65 %
201432.13 %19.8 %17.75 %
201330.71 %15.93 %12.37 %
201231.51 %19.94 %15.4 %
201129.6 %17.93 %8.67 %
201033.08 %21.38 %17.21 %
200936.59 %23.68 %18.36 %
200832.39 %20.64 %16.56 %
200731.98 %21.09 %18.74 %
200621.29 %8.04 %8.93 %
200522.2 %10.13 %8.76 %
200425.77 %13.15 %9.13 %

SCI Pharmtech Aktienanalyse

What does SCI Pharmtech do?

SCI Pharmtech Inc is a leading company in the pharmaceutical industry based in Zhejiang, China. The company was founded in 2003 and has since grown continuously. Today, the company employs over 100 employees and has become a key player in the global supply chain of pharmaceutical raw materials and intermediates. SCI Pharmtech Inc's business model is based on the development and production of high-quality pharmaceutical intermediates and active pharmaceutical ingredients, as well as the manufacturing of custom chemicals. The company specializes in the production and distribution process, offering its customers a comprehensive range of products that meet the highest quality and safety standards. SCI Pharmtech Inc is divided into various divisions, each specializing in specific product categories. The main divisions are API (Active Pharmaceutical Ingredients), intermediates, and custom synthesis. The API division produces active pharmaceutical ingredients for the pharmaceutical industry, which serve as the basis for drug manufacturing. The intermediates division offers pharmaceutical intermediates used in the synthesis of active pharmaceutical ingredients. The custom synthesis division provides tailored synthesis processes for customers in need of specific chemicals or intermediates. SCI Pharmtech Inc's product portfolio includes Acetamidomalonate, Carbamazepine, and Codergocrine Mesylate, among others. The company also offers custom synthesis services, involving complex chemical syntheses and innovative technologies. SCI Pharmtech Inc places great emphasis on quality and safety. The company operates according to international standards, including GMP (Good Manufacturing Practice), ISO (International Standards Organization), and CE (Conformité Européenne). SCI Pharmtech Inc's products undergo stringent quality controls to ensure compliance with the strict regulations of global pharmaceutical regulatory authorities. Another important concern of SCI Pharmtech Inc is sustainability. The company has developed a sustainable business strategy aimed at minimizing its environmental impact and conserving resources. This includes implementing efficient production processes, reducing energy consumption and CO2 emissions, as well as promoting environmental awareness among employees and customers. Overall, SCI Pharmtech Inc is a dynamic and innovative company specializing in the production of pharmaceutical intermediates and active pharmaceutical ingredients. The company takes pride in offering high-quality products that meet the highest quality and safety standards. Through its sustainable business strategy and adherence to international standards, SCI Pharmtech Inc has achieved an excellent reputation in the pharmaceutical industry and strengthened its presence in the global market. SCI Pharmtech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding SCI Pharmtech's Profit Margins

The profit margins of SCI Pharmtech represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of SCI Pharmtech's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating SCI Pharmtech's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

SCI Pharmtech's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When SCI Pharmtech’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about SCI Pharmtech Stock

How much profit has SCI Pharmtech made this year?

SCI Pharmtech has made 294.72 M TWD this year.

How has the profit developed compared to last year?

The profit has increased by -4.55% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does SCI Pharmtech publish its earnings?

SCI Pharmtech publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of SCI Pharmtech?

The profits of SCI Pharmtech are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of SCI Pharmtech?

You can learn more about the earnings of SCI Pharmtech by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does SCI Pharmtech pay?

Over the past 12 months, SCI Pharmtech paid a dividend of 0.22 TWD . This corresponds to a dividend yield of about 0.24 %. For the coming 12 months, SCI Pharmtech is expected to pay a dividend of 0.22 TWD.

What is the dividend yield of SCI Pharmtech?

The current dividend yield of SCI Pharmtech is 0.24 %.

When does SCI Pharmtech pay dividends?

SCI Pharmtech pays a quarterly dividend. This is distributed in the months of August, August, September, August.

How secure is the dividend of SCI Pharmtech?

SCI Pharmtech paid dividends every year for the past 1 years.

What is the dividend of SCI Pharmtech?

For the upcoming 12 months, dividends amounting to 0.22 TWD are expected. This corresponds to a dividend yield of 0.24 %.

In which sector is SCI Pharmtech located?

SCI Pharmtech is assigned to the 'Health' sector.

Wann musste ich die Aktien von SCI Pharmtech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SCI Pharmtech from 9/1/2023 amounting to 0.222 TWD, you needed to have the stock in your portfolio before the ex-date on 7/27/2023.

When did SCI Pharmtech pay the last dividend?

The last dividend was paid out on 9/1/2023.

What was the dividend of SCI Pharmtech in the year 2023?

In the year 2023, SCI Pharmtech distributed 0.417 TWD as dividends.

In which currency does SCI Pharmtech pay out the dividend?

The dividends of SCI Pharmtech are distributed in TWD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SCI Pharmtech

Our stock analysis for SCI Pharmtech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SCI Pharmtech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.